Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.
Sequoia Capital and Greenoaks co-led the oversubscribed round, with additional participation from Andreessen Horowitz (a16z) and other new investors. Alphabet maintained its backing with continued investment.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The round also included existing investors CapitalG, GV, MGX, Temasek, Thrive Capital, and the UK Sovereign AI Fund.
The company will use the capital to scale its drug design engine, IsoDDE, and expand its pipeline of drug candidates.
IsoDDE brings together foundational simulation models designed to function across multiple therapeutic areas and drug modalities to identify and refine molecules with drug-like properties.
Isomorphic Labs has reported positive preclinical findings across collaborative projects as well as internal programmes in immunology and oncology, preparing the pipeline for initial clinical testing.
Isomorphic Labs founder and CEO Demis Hassabis said: “When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI. Our drug design engine is generating molecules with unprecedented precision and speed.
“This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programmes towards clinical trials to deliver tangible impact for patients.”
Proceeds from the financing will also fund translational and clinical development infrastructure as drug candidates move towards trials.
In addition, the company is establishing a partner network to improve understanding of mechanistic disease biology, whilst building global infrastructure to support its bioengineering and computational biology operations.
Chris Molloy, CEO of the BioIndustry Association (BIA), said in an email to Pharmaceutical Technology: “Isomorphic Labs’ £3.8bn ($5bn) investment is not only a new peak for UK-founded companies; it is the largest ever venture capital raise for life sciences globally. This is a powerful vote of confidence in UK life sciences and a strong endorsement for our TechBio sector. Bringing breakthrough AI and drug discovery together offers extraordinary potential to tackle diseases that still lack effective treatments.
“When companies with exceptional science receive exceptional backing, it enables them to grow, scale and serve the world from here. Britain should be a place where it is common for scientific breakthroughs to become global businesses and, ultimately, life-changing medicines.”
In March 2025, the company raised $600m in its first external funding round as it pushes forward with AI-driven drug discovery.
